191 related articles for article (PubMed ID: 14695219)
1. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
[TBL] [Abstract][Full Text] [Related]
2. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.
Preynat-Seauve O; Contassot E; Schuler P; Piguet V; French LE; Huard B
Cancer Res; 2007 May; 67(10):5009-16. PubMed ID: 17510433
[TBL] [Abstract][Full Text] [Related]
5. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
Sotomayor EM; Borrello I; Tubb E; Rattis FM; Bien H; Lu Z; Fein S; Schoenberger S; Levitsky HI
Nat Med; 1999 Jul; 5(7):780-7. PubMed ID: 10395323
[TBL] [Abstract][Full Text] [Related]
6. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
7. Differential susceptibility of naïve versus cloned CD4+ T cells to antigen-specific and MHC-restricted anergy induction.
Liu QS; Zhang RH; Chu YW; Xiong SD
Sheng Li Xue Bao; 2003 Dec; 55(6):633-40. PubMed ID: 14695478
[TBL] [Abstract][Full Text] [Related]
8. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
9. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
Eck SC; Turka LA
Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression.
Wu HY; Monsonego A; Weiner HL
J Autoimmun; 2006 Mar; 26(2):116-26. PubMed ID: 16426816
[TBL] [Abstract][Full Text] [Related]
18. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
19. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
